ArticleBMC cancer2025
Machine learning-based differentiation of benign and malignant adrenal lesions using 18F-FDG PET/CT: a two-stage classification and SHAP interpretation study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preoperative PET/CT phenotype of gastric-type endocervical adenocarcinoma: integrated morphological, metabolic, serological, and explainable machine-learning analysis.European journal of nuclear medicine and molecular imaging · 2026Article
- Evaluation of adrenal incidentalomas: Current approaches, caveats, and unexplored issues.World journal of radiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAccurately distinguishing benign from malignant adrenal lesions remains a clinical challenge, especially in oncology patients with indeterminate imaging findings. This study aimed to develop and interpret machine learning (ML) models for classifying adrenal lesions based on 18 F-FDG PET/CT imaging and clinical parameters.
methodsA retrospective cohort of 255 patients undergoing 18 F-FDG PET/CT was analyzed. Imaging features-including adrenal SUVmax, SUVpeak, tumor diameter, CT attenuation, and tumor-to-liver SUVmax ratio (T/L SUVmax)-along with clinical variables were extracted. Two classification tasks were constructed: (1) differentiation of benign and malignant adrenal lesions; and (2) subtyping of malignant lesions into lung cancer metastases or lymphoma. Seven ML models were trained and evaluated using 10-fold cross-validation. SHAP (SHapley Additive exPlanations) analysis was applied to elucidate feature contributions.
resultsFor the benign/malignant classification, ensemble models (Random Forest, Bagging, XGBoost) achieved outstanding performance (AUC > 0.99), with Bagging yielding 100% recall. T/L SUVmax, adrenal SUVmax, and CT attenuation emerged as top predictors. In malignancy subtyping, the artificial neural network (ANN) attained the highest AUC (0.887) and F1-score (0.851). SHAP analysis highlighted distinct metabolic patterns, with lymphoma showing higher SUVmax and T/L ratios, and lung metastases associated with higher CT values.
conclusionMachine learning models based on PET/CT-derived features enable highly accurate and interpretable classification of adrenal lesions. Integrating metabolic and anatomical parameters improves diagnostic precision, while SHAP analysis offers clinical transparency, supporting personalized decision-making in adrenal lesion management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.